of tight junctions between adjacent BMEC surfaces. Intact tight junctions prevent passage of ionic substances as small as lanthanum (hydrated ionic diameter ∼0.8 nm) through this paracellular barrier [1] . Microvessels, the blood vessels between arteries and veins, are approximately 7.5 μm in diameter [2] , barely large enough for a red blood cell to squeeze through. Microvessels deliver blood to the brain from within the brain [3] .
There are 100 billion capillaries, approximately 600 km long, with a surface area of 20 m 2 within the human brain. These microvessels provide a blood supply within approximately 10 μm of every brain cell [4] , as illustrated in Figure 1 by the foreground and two background microvessels. They occupy approximately 2% of cortical brain volume and a greater space in some other brain regions [5, 6] . Pericytes extend over approximately 30% of the BMEC surface. Surrounding the BMECs and pericytes is a basement membrane, covering the abluminal (brain-side) BMEC surface ( Figure 1 ). Foot processes of astrocytes, one of the brain's glial cells, cover more than 90% of the abluminal basement membrane surface (Figure 1 ). Neurons interact with this cell complex to form the neurovascular unit ( Figure 1 ). For an NP to enter brain parenchyma from blood, it must either distribute through a BMEC (transcellular) or between BMECs (paracellular), as suggested in Figure 1 . The latter is not expected when the BBB is intact but can occur when the BBB is opened (leaky, e.g., there is increased space between adjoining BMEC surfaces). This occurs in cancer (at the blood-tumor barrier), Alzheimer's disease, traumatic brain injury, multiple sclerosis, infections, encephalitis, stroke, liver failure and other less common conditions [7, 8] . BBB opening can be produced by osmotic insult, for example, 25% mannitol infusion into a carotid artery that delivers blood directly to its ipsilateral hemisphere [9] or focused ultrasound in conjunction with systemically circulating microbubbles [10] .
The potential pitfall of experimental result misinterpretation
Given the intimate spatial relationship between the microvessels of the vascular compartment and brain parenchyma, visual demonstration of brain parenchymal entry in vivo or in situ requires ≤10 μm resolution. Alternatively, one could use methods that separate BBB components from brain parenchymal components. Failure to distinguish brain parenchymal NP entry from bulk brain can result in the interpretation that an NP has crossed the BBB when it may not have or did not to the extent implied. For example, IVIS demonstration of increased fluorescence in the head region from an NP component does not differentiate whether the NP is in the skull; the blood in the vessels surrounding and within the brain; associated with the luminal side of BMECs; within or between the BMECs; between the BMECs and basement membrane; within the basement membrane, pericytes or astrocyte foot processes; or in brain parenchyma.
There have been many studies addressing brain entry of many different NPs that concluded they entered the brain, without demonstration that they crossed the BBB and entered brain parenchyma. Considering the brain as the cranial contents, the claim of NP brain entry can be accepted if it is shown that the NP is in bulk brain. But this does not demonstrate brain parenchymal entry. For most studies, the methods employed were not able to differentiate NPs in the blood versus associated with BBB components versus residing in brain parenchyma, as differentiated in Figure 1 . Table 1 . Studies that reported the brain level of the nanoparticle or component(s) at multiple times after convection enhanced delivery. Mean residence time values were determined as described in nanoparticle kinetics in the brain.
Study summary MRT (h)
Ref.
The percent of radioactivity in the brain following CED of 82 nm 3 H-cholesteryl hexadecyl ether liposomes was determined 22 [83] The rat brain hemisphere that received CED of 0.06, 0.8 or 1.6 mg of 96-101 nm irinotecan-loaded nanoliposomes was perfused and homogenized, centrifuged,and irinotecan analyzed by the HPLC. Half-life of the three doses was 6.7, 10.7 and 19.7 days, respectively 108, 181and 400 [81] Brains from rats that received CED of 105-122 nm topotecan-loaded liposomes was perfused, the infused hemisphere removed, homogenized, centrifuged and topotecan analyzed by the HPLC. Half-life was 1.5 days 44 [84] The rat brain hemisphere that received CED of a mixture of 95-110 nm doxorubicin-loaded pegylated liposomes or irinotecan-loaded nanoliposomes was perfused, homogenized, centrifuged and irinotecan and doxorubicin analyzed by the HPLC. Half-life was 10.9 and 16.7 days, respectively 273 and305 [79] Local retention of radioactivity after intratumor CED of 135 nm 186 Re-loaded liposomes was determined in rat brain by gamma camera. Half-clearance time was 54.6 h 50 [85] Brain MRI was obtained after CED of human serum albumin-, PEG-and methotrexate/human serum albumin-coated 20 nm ␥ -Fe2O3 NPs 190, 184and 198 [80] IVIS imaging was conducted after CED of EGFR-coated quantum dot-containing immunoliposome hybrid NPs to mice with brain tumors 97 [86] Positron emission tomography imaging was conducted after CED of 71 and 147 nm [ 18 F]-fluorobenzylamine, NHS-PEG-biotinylated, avidin-modified PLGA NPs to rats. Half-life was 111 min 0.39 [87] Rat brain containing the region of CED of 175 nm carboplatin-labeled fluorescein-PLGA NPs was homogenized and platinum determined by ICP-MS 18 [88] The hemisphere that received CED of 60-100 nm radiosensitizer (VE822)-loaded PEG-conjugated, poly(u-pentadecalactone-co-p-dioxanone) NPs, of varying PEG polymer ratios, was analyzed by LC-MS for VE822. Half-life was 12 h, 2 and 5 days 46, 61 and 68 [89] Fluorescence images of mice brain sections were obtained after intrastriatal CED of Cy5.5 fluorophore-labeled peptide-based nanofibers (5-nm width, 100, 400 and 1000 nm length) 20, 25 and 29 [29] MRI imaging was conducted for 48 h after CED of 54-nm iron oxide chitosan-PEG NPs modified with a glioma-targeting ligand to mice-bearing brain tumors. Signals near the point source of the infusion of NP without and with ligand were used to calculate the MRT 3.4 and4.8 [90] CED: Convection-enhanced delivery; HPLC: High-performance liquid chromatography; ICP-MS: Inductively coupled plasma mass spectrometry; IVIS: In vivo imaging system; LC-MS: Liquid chromatography-mass spectrometry; MRT: Mean residence time to the last sample; NHS: N-hydroxysuccinimide; NP: Nanoparticle; PEG: Polyethylene glycol; PLGA: Poly(D,L-lactide-co-glycolide).
similar to the BBB, creating the BCSFB between blood and CSF. There is little barrier to distribution between CSF and the brain, so substances injected into the CSF compartment, or able to cross the BCSFB, readily diffuse into the brain proximal to the CSF compartment. Material entry into the nervous system, including the brain, might also be achieved by its introduction into the CSF compartment. In the human, this is most often accomplished by injection into CSF in the spinal region. Given CSF flow, NP injection into CSF would not be expected to persist for a long time compared with introduction into brain parenchymal space. As distribution from CSF into the CNS (brain and spinal cord) is by diffusion, and against extracellular fluid flow toward CSF, significant distribution very far into the brain would not be expected. Demonstration of successful NP distribution into brain parenchyma via this route would require similar techniques as apply to NP introduction into blood.
Convection-enhanced delivery of solutions into brain extracellular space
A method to directly deliver solutions into the brain is convection-enhanced delivery (CED). In CED, the tip of a catheter is stereotaxically inserted into the brain through a hole in the cranium. A solute (drug or NP)-containing solution is infused through the catheter by a pump. Solute release from the catheter tip into brain extracellular space displaces extracellular fluid. The solute distributes through brain extracellular space surrounding the catheter tip by bulk flow to create a radial distribution up to a few centimeters. After termination of the infusion, the solute may continue to redistribute by bulk flow and diffusion as it is being locally cleared. CED has advantages of bypassing the BBB enabling brain parenchymal delivery of drugs that do not cross the BBB, delivery to a target site that can be deep within the brain and creation of much higher regional than distal brain and systemic drug concentration. It is most commonly used to treat glioblastoma multiforme, a brain cancer that has a poor prognosis [26] [27] [28] . Small molecules are cleared within 72 h [29] , whereas some NPs have been found to persist for much longer (Table 1 & Supplementary Figure 1 ). Table 2 . Visual methods that might be used to image brain nanoparticle distribution and their reported resolution.
Method
Resolution Ref.
High-resolution brain MRI ≥120 μm [91] Photoacoustic microscopy 20-100 μm [37] IVIS spectrum 20 
The nasal cavity route of delivery directly to the CNS
There is only one site where the nervous system is directly exposed to the external environment of mammals, where direct uptake of NPs into the nervous system might occur. This is the roof of the nasal cavity where the olfactory neuron and the maxillary branch of the trigeminal neuron have terminals with receptors that mediate the perception of sensory stimuli, including smell. This route of administration, introducing test material into the nose (intranasal), is being investigated for NP entry into the brain, to bypass the BBB. Demonstration of NPs in these sensory neurons ex vivo (e.g., by electron microscopy visualization or elemental analysis under conditions that rule out dissolution or degradation that releases NP components), or of NPs within the nerve when it is in situ, provides confidence of nerve entry. The olfactory and trigeminal neurons are surrounded by CSF, so suggestion of NP in the region of the nerve, for example, from an NP fluorescent molecule, does not unequivocally show nerve entry. Although neuropeptides have been shown to enter CSF directly from the nasal cavity, this route was shown to not contribute to uptake of 110 nm 6-coumarin-loaded (for visualization) PEG-poly(lactic acid) NPs [30] . There have been demonstrations of NP uptake by the olfactory or trigeminal nerve. NPs often accumulate in the olfactory bulb, with little or no distribution across the synapse between the olfactory bulb and the next neuron of the olfactory system that would enable distribution to distal brain regions (e.g., the pyriform cortex, amygdala, thalamic and hypothalamic nuclei, and hippocampus) after intranasal administration. Olfactory bulb accumulation was shown with colloidal gold [31, 32] , 13 C carbon [33] , nanoscale manganese oxide [34] and quantum dots [35] . Distribution of quantum dots from the nasal cavity to the olfactory bulb was attributed to microtubule-mediated fast axonal transport (200-400 mm/day), because axonal flow is too slow to account for the timecourse of its appearance in the olfactory bulb [35] . Based on the olfactory nerve length from the nasal cavity to the olfactory bulb (∼5 and 8 mm in mice and rats, respectively) fast axonal transport could traverse this with an NP in approximately 26-40 min. Much more time would be required for neuronal NP transport from the nasal cavity to distant brain regions, such as the striatum. Rapid appearance of NPs or NP components in distant sites can be attributed to absorption from the nasal cavity into systemic circulation followed by distribution into the brain. Translocation of NPs from the nasal cavity to the brain is low. Gamma counting of whole brain 24 h after intranasal 111 In-labeled protein NP suggested approximately 0.2% of the dose was in the brain, assuming stability of the 111 In-NP complex [36] . No studies were found demonstrating NP entry into brain parenchyma beyond the olfactory bulbs after intranasal administration.
Methods to demonstrate NP brain parenchymal entry
To definitively claim that an NP has entered brain parenchyma requires methods that differentiate NP distribution in brain parenchyma from blood within the brain and BBB components. One approach is to use visual methods.
Visual methods to demonstrate NP brain parenchymal entry Table 2 lists some visual methods and their optimal resolution. High-resolution brain MRI does not provide, even under optimal conditions, sufficient resolution to differentiate NP localization between parenchymal versus nonparenchymal sites. It would not be able to characterize NP morphology, size or chemical identity. Photoacoustic imaging (tomography) is a hybrid imaging modality that integrates optical contrast with highultrasonic spatial resolution in deep tissue. It can provide noninvasive images of the entire brain with less than msec temporal resolution [37] , based on the light absorption properties of the tissue and material (e.g., NPs) within it. Although useful for NP-assisted imaging, for example, of brain tumors, it lacks sufficient resolution to differentiate NP localization between parenchymal versus nonparenchymal sites.
The IVIS spectrum in vivo imaging system combines 2D and 3D optical tomography into a single platform to visualize fluorescence and bioluminescence. It has been extensively used to demonstrate the intensity of fluorescent NPs in organs in vivo and ex vivo. Intensity in the head region has been claimed by many as evidence of the NP in the brain. It is noninvasive and can be used with living organisms. However, even if used to localize NPs in ex vivo tissue, it does not have sufficient resolution to differentiate NP localization between parenchymal versus nonparenchymal sites.
Mass spectrometry imaging (MSI) includes many techniques, such as laser desorption/ionization mass spectrometry, matrix-assisted laser desorption ionization, (time-of-flight) secondary ion mass (SIM) spectrometry and desorption electrospray ionization. It has been used with surface-functionalized gold-or gadolinium-containing NPs to localize organics such as lipids, metabolites and proteins in the brain. Although some forms of MSI have submicron resolution (e.g., SIM), no reports were found using MSI to verify brain parenchymal NP localization.
Super-resolution microscopy utilizes fluorescent microscopes in a variety of approaches, categorized as those that approach the diffraction limit (0.25 μm in the focal plane) and those that break the diffraction limit by turning fluorescent markers on and off. In the latter rather than all fluorescent molecules emitting simultaneously (as occurs in conventional fluorescence microscopy), a small subpopulation is excited so that emission from neighbors does not overlap, enabling isolation of individual emitters [38] . Approaches include stochastic optical reconstruction microscopy, direct stochastic optical reconstruction microscopy, photoactivated localization microscopy, fluorescence photoactivated localization microscopy and ground-state depletion with individual molecule return. Super-resolution microscopy has been used to image the NP protein corona [39, 40] and localize NPs in cells [41, 42] , but no reports were found of in vivo, in situ or ex vivo NP localization.
Hyperspectral imaging combines imaging and spectrophotometry by capturing spectral data of infrared and visible light reflected by samples at each pixel in an enhanced dark-field microscopic image. For this to differentiate vascular versus parenchymal NP localization, an enhanced dark-field microscopic image needs to be interpreted first to identify the region of interest, then hyperspectral imaging employed to provide spectrophotometric data. This was demonstrated in studies that showed cellular sites of functionalized gold NPs [43] ; studies that included cellular, C. elegans, and Japanese medaka NP distribution cited by Roth [44] ; and porcine skin uptake of metal oxide NPs [45] . This approach might enable differentiation of NP localization between brain parenchymal versus vascular sites, but no such studies were found.
Fluorescence microscopy visualizes fluorescent tags or incorporated molecules (e.g., doxorubicin and paclitaxel). With the exception of transmission electron microscopy (TEM), the only studies using a method in Table 2 that appear to have differentiated NP parenchymal from vascular space distribution used fluorescence microscopy and CLSM. Using fluorescence microscopy, Mulik et al. saw fluorescent-labeled NPs within brain cells [46] .Åslund et al. used CLSM to image fluorescent dye-containing NPs, and tomato lectin-labeled blood vessels, and saw NP fluorescent dye outside of the brain microvasculature [47] . Some details of these studies and those reported by others who used CLSM are below and/or in Table 4 [22, 24, 25, [47] [48] [49] [50] [51] [52] [53] [54] [55] .
Electron microscopy, typically TEM, is not only the best technique to characterize prepared NPs, it is also amenable to physicochemically identify and characterize NPs in samples obtained from biological environments [56] [57] [58] . It provides the greatest resolution among the options in Table 2 , and when equipped with capabilities such as high-angle annular dark-field detection, energy dispersive x-ray spectroscopy or electron energy loss spectroscopy, it enables chemical characterization.
The benefits of light microscopy (including identification of biological structures and location of regions of interest and fluorescent labels) have been combined with the benefits of electron microscopy (to provide NP localization and physicochemical information) in correlative light and electron microscopy (CLEM) [59] . The two approaches were independently used to locate NPs in a murine brain tumor model [60] . CLEM has been developed in a single instrument and used to localize NPs in cultured non-neuronal cells [61] . No studies were found utilizing CLEM to investigate NP brain parenchymal entry.
Several of the above methods are based on detection of a label added to the NP, often a fluorescent molecule or metal/metal oxide. Correct interpretation of NP localization, when based on an added label, requires NP preparation that does not contain free label (which can be removed by dialysis) and understanding the label stability in vivo. Fluorescent molecules are susceptible to loss of their signal due to quenching (due to interaction with local molecular environmental components) and photobleaching (excitation light-induced destruction of the excited fluorophore). Persistent association (stability) of the label and the NP in vivo is required to attribute label signal to NP localization. Label dissociated from the NP will yield a different distribution than the label-NP complex. Covalent binding of label to an NP decreased label release, compared with encapsulation of the label [62] . Incorporation of the label in the NP core did not produce changes in the NP surface properties [63] . Label dissociation from a biodegradable polymer NP would be expected over time. Label dissociation can be assessed in vitro by incubation of the labeled NP with brain homogenate [30] or separation of the NP and brain components from the released label, for example, by NP centrifugation, and detection of label in the supernatant. Other considerations include the potential for the label to alter the physicochemical properties of the NP and its resultant distribution and biological tolerance to the label. More in-depth discussions can be found in [64, 65] .
Procedural methods to demonstrate NP brain parenchymal entry Methods are available to assess whether NPs introduced into the vasculature perfusing the brain are associated with BBB components and/or crossed the BBB to enter brain parenchyma. The in situ brain perfusion technique can be used to determine NP entry rate and extent of distribution into bulk brain, multiple bulk brain regions and/or the choroid plexus, ipsilateral to the carotid artery perfused after short-term (few minutes or less) intracarotid infusion [66] . An intracarotid perfusion rate sufficiently high to prevent blood from entering the perfused carotid artery is used, therefore preventing blood from entering the brain hemisphere perfused by that artery. This enables control of the chemical environment of the material tested (therefore its chemical form [speciation]), based on the perfusion fluid composition and avoidance of blood exposure. Preventing blood exposure avoids potential NP biotransformation (e.g., corona coating by plasma proteins, dissolution or particle breakdown) that might change its surface properties and brain uptake. Although the in situ brain perfusion technique removes blood from the brain vasculature, it does not distinguish NP distribution associated with the BBB versus brain parenchyma, nor choroid plexuses from brain unless they are separated.
The capillary depletion method is intended to separate BBB components from brain parenchyma, to produce capillary-depleted brain parenchyma [67] . This is often conducted with brain tissue obtained using the in situ brain perfusion technique but can be used with brain tissue obtained by other methods that remove blood from the brain. The methods are described in detail in [68] . The capillary depletion method uses centrifugation of brain homogenate in dextran that separates the BMECs into the pellet (along with brain nuclei and erythrocytes if blood was not perfused from the brain) from the supernatant that contains brain cells and brain extracellular fluid. Presence of the test material in the supernatant is taken as evidence that it has transcytosed the BBB into brain parenchyma. This method was employed to ascertain the fraction of 190-nm poly(n-butyl cyanoacrylate) (PBCA)-coated doxorubicin-loaded NPs that entered brain parenchyma [69] . Doxorubicin was seen in the brain fraction after intravenous administration in NPs but not when doxorubicin solution was administered with 1% polysorbate 80 (intended to open the BBB). Coating the NPs with 1% polysorbate 80 increased the doxorubicin supernatant to pellet ratio, suggesting the surfactant-coated PBCA NPs entered brain parenchyma. Employing the capillary depletion method after whole body perfusion to remove blood, it was shown that the percentage of the injected dose of [ 111 In-DTPA-multiwalled carbon nanotubes (median diameter: 18.9 and length: 500 nm) decreased in brain capillaries but not brain parenchyma over 24 h [70] . The capillary depletion method was used to obtain curcumin for LC-MS/MS analysis from mouse brains after oral dosing of a curcumin-containing NP. The report does not state if the brain was perfused prior to harvest. If not the supernatant fraction would be expected to include blood plasma contents that could have contained some/all of the curcumin [71] . The capillary depletion method was used to demonstrate that cationic bovine serum albumin-coated biodegradable polymersomes (∼100 nm, composed of PEG-and maleimide-PEG-poly(ε-caprolactone), loaded with coumarin-6) entered brain parenchyma. The supernatant fraction increased from a half to 1 h and was fairly stable for 4 h, and increased over the 4 h in relation to the pellet (vascular fraction) [72] . Capillary depletion was used in transcardially perfused mice to assess the influence of transferrin-receptor antibody density on gold NPs and platinum-containing liposomes to enter brain parenchyma [73] . 2.5 h after intravenous injection, gold and platinum in the parenchymal fraction were approximately 27 and 22% of the combined parenchymal and capillary fractions, respectively. In contrast to demonstrating brain parenchymal entry, the capillary depletion method suggested nearly all of 5-nm ceria in the brain was associated with the capillary endothelial cells, consistent with EM observations of nanoceria adhered to the luminal side of blood vessel walls in the brain, noted above [21] . Table 3 . A classification of results demonstrating brain versus. brain parenchymal entry.
Level
Description of results Interpretation 1 NP component (e.g., fluorescent dye, element) in bulk brain or ex vivo brain not perfused of blood. Determined by methods such as IVIS, radioactivity, NAA, ICP-MS, AAS or HPLC A NP component was in bulk brain 2 NP component (e.g., fluorescent dye, element) in bulk brain or ex vivo brain perfused to remove blood. Determined by methods such as IVIS, radioactivity, NAA, ICP-MS, AAS or HPLC A NP component was in bulk brain, but not in the blood within the brain 3 Intact NP in bulk brain not perfused of blood. Determined by methods such as bulk brainhomogenization, NP isolation and verification (e.g., visual, perhaps also requiring chemical)
The NP was in bulk brain 4 Intact NP in bulk brain perfused to remove blood. Determined by methods such as bulk brain homogenization after perfusion to remove blood, NP isolation and verification (e.g., visual, perhaps also requiring chemical)
The NP was in bulk brain, but not in the blood within the brain 5 NP component isolated from brain parenchyma. For example, using the capillary depletion method of brain perfused to remove blood to obtain brain parenchyma and a method to identify the NP component, for example, radioactivity, ICP-MS, AAS or HPLC. For example, microdialysis to recover an NP component from brain extracellular fluid, in the presence of an intact BBB A NP component was in brain parenchyma 5 NP component (e.g., fluorescent dye, element) visualized in brain areas or cells not associated with brain vasculature. Determined by methods such as MSI, single-molecule localization microscopy, hyperspectral imaging or CLSM A NP component was in brain parenchyma 6 Intact NP isolated from brain parenchyma. For example, using the capillary depletion method of brain perfused to remove blood to obtain brain parenchyma and a method to verify intact NPs (e.g., visual, perhaps also requiring chemical)
The NP was in brain parenchyma 6 Intact NP visualized in brain areas or cells not associated with brain vasculature.
Determined by methods such as TEM, with chemical verification, such as EDS or EELS
The NP was in brain parenchyma
The level of demonstration of nanoparticle brain or brain parenchymal entry is in the first column. AAS: Atomic absorption spectroscopy; BBB: Blood-brain barrier; CLSM: Confocal laser scanning microscopy; EDS: Energy dispersive x-ray spectroscopy; EELS: Electron energy loss spectroscopy; HPLC: High-performance liquid chromatography; ICP-MS: Inductively coupled plasma-mass spectrometry; IVIS: In vivo imaging system; MSI: Mass spectrometry imaging; NAA: Neutron activation analysis; NP: Nanoparticle; TEM: Transmission electron microscopy.
NP components have been sampled from the brain using microdialysis probes [74] [75] [76] [77] . In the presence of an intact BBB, it is assumed that this technique samples brain extracellular space. Microdialysis probes with 30 and 100 kDa molecular weight cutoff membranes would be expected to allow penetration of up to 5-8 and 8-14 nm (depending on membrane composition) diameter spherical particles and molecules released from NPs. The appearance of an NP component in the dialysate from a probe would not conclusively demonstrate NP distribution into brain parenchyma. None of the above studies demonstrated that intact NPs were recovered in the dialysate.
Level of demonstration of NP brain or brain parenchymal entry & critical review of study claims
Convincing demonstration of brain parenchymal entry is limited to in vivo studies. In vitro BBB models do not recapitulate BBB complexity. They lack all of its cell composition, cell interactions, cell spatial relationships and magnitude of resistance to distribution across them. Therefore, this report is limited to in vivo, in situ and ex vivo brain studies. Many reports published within the past 5 years were identified by a SciFinder search of the terms NP and brain, a SciFinder search of the terms NP and BBB for reports published in 2019, and a PubMed search of NPs, drug delivery systems and brain parenchyma. The reports were reviewed, summarized and critiqued for evidence supporting claims in the report and classified for the level of demonstration of NP brain or brain parenchymal entry, as defined in Table 3 . Some reports published more than 5 years ago that are informative for their demonstration of NP brain parenchymal entry and/or reported brain NP concentration at multiple times are included. The results are in Table 4 .
NP kinetics in the brain
Endocytosis is the prevalent mechanism that mediates NP transport across the intact BBB. It would not be anticipated that after NPs cross the BBB and enter brain parenchyma they would be rapidly cleared from that compartment [78] . After NP infusion directly into the brain by CED, HPLC determination of two components showed clearance half-lives of 250-400 h ( Table 1) [79] . MRI-determined NP distribution volume after CED decreased 50% in approximately 250 h (Table 1) [80] . Some details of these and other studies that reported brain NP or component levels at multiple times after CED are in Table 1 . Brain clearance half-life was shown to be dose 'Focused ultrasound and magnetic targeting synergistically delivers therapeutic MNPs across the blood-brain barrier to enter the brain' a Whole brain was prepared for ICP-OES iron and HPLC epirubicin determination after iv. injection of 12-nm magnetic NPs into rats whose BBB had been opened by iv. injection of microbubbles and focused ultrasound. b TEM of similarly treated rats with brain tumors showed electron densities inside tumor cells and macrophages a ICP-OES and HPLC demonstrate bulk brain but not parenchymal entry; 1. b TEM demonstrates delivery across the BBB in the presence of BBB opening, assuming the electron densities are iron; 6 11 [106] 'NP deposits were widely distributed throughout brain, with apparent cellular uptake' a Microscopic assessment of sections from rat brain after intranasal dosing of 299-nm fluorescent-and ovalbumin-loaded cationic liposomes revealed the label in the striatum and substantia nigra. b Protein immunohistochemistry of perfused rat brain demonstrated protein and tyrosine hydroxylase co-localization in striatum and substantia nigra. c Gamma counting of whole brain after intranasal dosing of 50 μg 111 In-labeled NP in 1 or 2 μg/μl suggested approximately 0.2% of the dose was in the brain, assuming stability of the 111 In-NP 'In vivo brain distribution . . . monitored by a real-time fluorescence imaging system'
The whole rat and ex vivo brain were bioluminescence imaged using IVIS and fluorescence microscopic images obtained of brain sections after iv. injection of 190-210 nm fluorescent dye-labeled solid lipid particles Imaging demonstrates bulk brain distribution; 1 0.45 [108] Brain delivery Fluorescence intensity was determined in ex vivo organs from perfused rats after intranasal dosing of odorranalectin-conjugated fluorescent-labeled 90-nm PEG-PLGA NPs
Fluorescence intensity of brain demonstrates bulk brain delivery; 2
[109]
Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Table 3 . The numbers after the sentences in column 3 refer to the level of demonstrated NP brain entry. AAS: Atomic absorption spectroscopy; BBB: Blood-brain barrier; BBTB: Blood-brain tumor barrier; BMEC: [111] 'Suggest that the OX-26-coated NPs were taken up by the brain'
Microdialysis samples were obtained from the ventral hippocampus for fluorescence detection of FITC-dextran after iv. administration of 140-160 nm CD71/OX26-coated FITC-dextran loaded methoxy-PEG-poly(lactic acid) NPs
NPs were too large to diffuse through the microdialysis membrane suggesting FITC-dextran release; 5, assuming intact BBB 21 [74] 'Brain endothelial uptake and possibly parenchymal accumulation'
CLSM of fixed brain sections after carotid artery (in situ brain) perfusion and washout of perfusate or iv. injection of fluorescent dye-labeled, polyethylenimine/oligonucleotide-containing liposomes showed fluorescence associated with BMECs and in the perivascular space between the BMEC membrane and parenchymal basement membrane NP or a component seen beyond BMECs but not in brain parenchyma; 2 [51] 'NPs possess an appreciable BBB penetrability'
Microdialysis samples were obtained from the right ventrolateral periaqueductal gray for fluorescence detection of FITC-neurotoxin after intranasal dosing of 145-nm chitosan-modified PLA FITC-neurotoxin-containing NPs NPs were too large to diffuse through microdialysis membrane suggesting FITC-neurotoxin release; 5, assuming intact BBB 3.3 [75] 'Accumulation was achieved in the brain'
Whole brains from mice were homogenized, proteins precipitated, and camptothecin determined by HPLC after iv. injection of 160 nm camptothecin-containing solid lipid NPs.
HPLC analysis demonstrates bulk brain accumulation; 1 7.7(7.0) [112] '[Palmitoyl dalargin] was detectable . . . in the brain' 'pDal is clearly located in the brain parenchyma' a Whole brains were homogenized, proteins precipitated and palmitoyl dalargin measured by LC-MS in rats after iv. injection of palmitoyl dalargin fibers. The authors claim brain parenchymal entry because brain concentration was greater than can be accounted for by blood, and slower clearance from brain than blood. b Coherent anti-Stokes Raman scattering microscopy revealed pDal fibers within brain parenchyma a LC-MS of NP component in bulk brain does not rule out BMEC adsorption or incorporation; 1. b Microscopy demonstrated brain parenchymal fiber entry; 6 0.86(0.17) [113] 'Ag detected in the brain and passing through the blood-brain barrier (i.e., not localized in the vessels and capillaries) constitutes no less than 93% of the total content of Ag in the organ'
Silver and gold were determined by NAA in brain of exsanguinated rats after 14 or 28 daily intragastric administrations of 35-nm silver and gold NPs. The authors calculated brain metal from its concentration in blood and brain blood mass Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Table 3 . The numbers after the sentences in column 3 refer to the level of demonstrated NP brain entry. AAS: Atomic absorption spectroscopy; BBB: Blood-brain barrier; BBTB: Blood-brain tumor barrier; BMEC: Assessing nanoparticle brain entry Review Table 4 . Brain nanoparticle distribution study claims, summary, critique, support for the claims and level of brain or brain parenchymal entry. (cont.).
Claim

Study summary Critique, support for claim and level of demonstrated NP brain entry MRT (h) Ref.
'BBB-penetrating cancer cell-targeting delivery system' a Whole animal and ex vivo brain IVIS imaging were conducted after iv. 85-nm fluorescent-labeled, doxorubicin-loaded desoctanoyl ghrelin and folate conjugated-polymersome administration to brain tumor-bearing mice. b Brains from brain tumor-bearing perfused rats were homogenized, proteins precipitated and doxorubicin determined by HPLC after iv. injection of 85 'We . . . demonstrated the ability of these [gelatin NPs] to pass into the brain parenchyma following intranasal administration' SEM of rat brain 6 h after intranasal administration of 184-nm gelatin NPs showed clusters of approximately 40-nm spherical particles in the olfactory tract, cortex, striatum, amygdala and hypothalamus as evidence of NP brain parenchymal entry
Assuming the observed particles were gelatin NPs, perhaps smaller due to tissue processing, the results suggest brain parenchymal entry; 5 [117] 'Migration to brain parenchyma' 'albumin modulates the transport across the blood-brain barrier' a Whole brain radioactivity was determined by gamma-scintigraphy of isolated mouse brain after iv. albumin-coated 15-nm 198 Au NP injection. b Brain confocal microscopic images were obtained after iv. fluorescent-labeled albumin-coated 198 Au NP injection a Whole brain radioactivity does not verify transport across the BBB into brain parenchyma; 1. b Resolution is not sufficient to differentiate vascular from brain parenchymal distribution; 1 21(5.1) [17] 'Particles that actually crossed the BBB'
Gold was determined by flame AAS analysis in brain from mice that received iv. injection of 20-nm insulin PEG-coated gold particles. Brain gold was calculated from its blood concentration and brain-blood volume This does not account for gold associated with BMECs that the authors hypothesize accounted for gold in the brain at late time points; 1 11(blood did not decrease over 48 h) [118] Coumarin distribution to the glioma region a Brains from glioma-bearing mice were homogenized, coumarin-6 extracted and quantified by HPLC after iv. injection of 94-nm coumarin-6, L-13R␣2 ligand-coated PEG-PLGA NPs. b Fluorescence spots were seen in the brain a HPLC analysis of NP component demonstrates bulk brain distribution; 1. b Microscopy resolution only sufficient to demonstrate brain distribution; 1 [119] Brain uptake Radioactivity determined by gamma-scintigraphy of isolated whole mouse brain after iv. injection of 9-and 40-nm diameter, 396-and 268-nm length [ 111 In]-DTPA-multiwalled carbon nanotubes Radioactivity demonstrates distribution of NP or component in bulk brain; 1 [120] 'Gold would presumably not be cleared from brain in such a short timeframe if it has entered the brain parenchyma'
Brains from mice were digested and gold determined by ICP-OES after iv. injection of 80-nm biodegradable polymeric micelles with 5 nm gold NP cores ICP-OES results of NP component in bulk brain do not show brain parenchymal entry; 1 43(7.7) [78] Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Table 3 . The numbers after the sentences in column 3 refer to the level of demonstrated NP brain entry. AAS: Atomic absorption spectroscopy; BBB: Blood-brain barrier; BBTB: Blood-brain tumor barrier; BMEC: Table 4 . Brain nanoparticle distribution study claims, summary, critique, support for the claims and level of brain or brain parenchymal entry. (cont.).
Claim
Study summary Critique, support for claim and level of demonstrated NP brain entry MRT (h)
'Demonstrated that the NPs could cross the BBB' CLSM images were obtained of brain tissue cryosections, stained with tomato lectin to label blood vessels, from rats that received iv. microbubbles and focused ultrasound to open the BBB before iv. injection of 177-nm fluorescent dye-containing PBCA NPs Fluorescent spots attributed to the fluorescent dye near the blood vessels suggest NPs crossed the BBB in the presence of opened BBB; 6 [47] 'The peptide was able to diffuse outside the BBB, while NPs were restricted to the vessel endothelium'
CLSM images of brain sections with antibody-stained BMECs from mice iv. dosed with 35-nm fluorometric dye-labeled amphiphilic polymer-coated iron oxide NPs containing a fluorometric dye-labeled antiretroviral drug enabled distinction among microvessels, NPs and drug. The NPs and BMECs were co-localized. The antiretroviral drug was seen within and outside of the vascular compartment, in brain parenchyma
Peptide fluorescence was seen in brain parenchyma; 5 [24] 'Distributed into the brain tissue' The capillary depletion method was used to obtain a non-BMEC fraction of mouse brains for LC-MS/MS curcumin analysis after oral dosing of 139, 312 and 412 nm uncoated, chitosan-and N-trimethyl chitosan-coated, curcumin-loaded solid lipid NPs
Most of the whole brain curcumin was in the supernatant fraction, not associated with BMECs, but could have come from blood; 1 [71] 'BBB penetration by AuNPs' a Gold content was determined by ICP-MS in brain from perfused rats that received ip. injection of 1. The increase of brain iron from days 1 to 7 'suggested the smaller IOMNs crossed the blood-brain barrier'
Iron was quantitated by AAS in solubilized whole organs from mice that received iv. 10-nm carboxyl-coated iron oxide magnetic NPs AAS results of NP component in bulk brain do not verify BBB crossing; 1
Increased from 24 to 168 h after injection [121] 'Exosome delivered anticancer drugs crossed the BBB and entered into the brain' Fluorescent dye-, paclitaxel-or doxorubicin-labeled mouse-derived Ͻ50 nm BMEC exosomes were iv. injected into zebrafish transgenic for vasculature GFP expression
CLSM suggests NP fluorescence and shows drug fluorescence outside of the vasculature; 5 [48] 'Nose-to-brain transport' Cyclosporine A was extracted from homogenized olfactory bulb and hind brain samples and quantitated by LC-MS/MS after intranasal dosing of 272-nm nanoemulsion to the rat LC-MS/MS NP component shows bulk brain distribution; 1 2.4 and 2.6 [122] 'NPs were capable of penetrating cell membranes and entering cellular compartments'
Brains from mice with green fluorescent protein-expressing tumors were imaged using CLSM after iv. injection of 165-nm fluorescent dye-labeled poly(amineco-ester) terpolymer NPs. PECAM (in BMECs) was labeled. NPs were visualized around tumor blood vessels and within a cell Brain parenchymal NP entry shown in tumor cells; 6 [49] Brain accumulation at the site of injury Whole-body IVIS images were obtained after iv. administration of approximately 170-nm fluorescent-labeled siRNA-containing biodegradable mesoporous silica, encapsulated in graphene oxide nanosheets. Fluorescence was seen in the hemisphere of mice with damaged brain Greater fluorescence in brain at the injury site supports brain accumulation; 1 [123] 'NP was obviously accumulated in brain'
Imaging demonstrated mouse whole brain fluorescence after iv. injection of approximately 180-nm cyclic peptide-modified fluorescence dye-loaded PEG-poly(lactic acid) NPs Fluorescence demonstrates brain accumulation; 1 [124] Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Table 3 . The numbers after the sentences in column 3 refer to the level of demonstrated NP brain entry. AAS: Atomic absorption spectroscopy; BBB: Blood-brain barrier; BBTB: Blood-brain tumor barrier; BMEC: Assessing nanoparticle brain entry Review Table 4 . Brain nanoparticle distribution study claims, summary, critique, support for the claims and level of brain or brain parenchymal entry. (cont.).
Claim
Study summary Critique, support for claim and level of demonstrated NP brain entry MRT (h)
'Delivery of . . . NPs across the blood-brain barrier'
CLSM images of mouse brain after oral administration of 60-nm PEG-coated, curcumin and piperine-coloaded glyceryl monooleate NPs showed intracellular NPs Neuronal intracellular NPs supports delivery across the BBB; 6 18(13) [50] NP were 'taken up into the brain cells'
Rats with BBB opened by focused ultrasound received iv. 22-nm fluorescent probe-labeled low-density lipoprotein NPs. Fluorescence microscopy images were interpreted as showing punctate fluorescent staining within brain cell cytosol
Brain parenchymal NP uptake appears to be shown in the presence of an opened BBB; 6 [46] 'NP retention in brain tumors' a IVIS-imaged whole and ex vivo mouse brain showed accumulation in glioma after iv. 33-36-nm fluorescent-labeled, penta-amino acid-or 2-cyano-6-amino benzothiazole-, or both, coated gold NP injection. b Glioma were excised for gold quantification by ICP-MS. c TEM images showed intracellular densities a Whole brain results using this method show NP retention in brain tumors; 'Brain microvessel endothelial cell targeting'
Brains of mice were perfused and prepared for immunohistochemistry and fluorescence imaging after 2 iv. injections 1 h apart of 50-nm transferrin antibody-conjugated mesoporous silica NPs. BMECs were labeled with biotinylated potato lectin detected by fluorescent-labeled streptavidin. One hour after the second injection NPs were associated with the BMECs. There was no evidence brain parenchymal penetration NP brain microvessel targeting was demonstrated; 3 [129] 'Enhanced drug transport across BBB' a Iron was determined by AAS in mouse organs after iv. injection of 80-nm dextran-spermine superparamagnetic-core NPs and 96-nm transferrin-coated NPs b Tissues were stained with Prussian blue to visualize iron localization a AAS results of NP component in bulk brain do not verify transport across the BBB; 1 b Resolution not sufficient to confirm iron transport across the BBB; 1
Increased from h 24 to 168 after injection [130] 'To further confirm the translocation of CLS-PEG NPs across the BBB' 'C6 to pass through the blood-brain barrier' a Rat brains were analyzed by fluorescence analysis after iv. injection of 176-nm coumarin-6-labeled cholesterol-containing PBCA NPs and 185-nm particles also containing PEG. b Brains from perfused rats were viewed using CLSM that showed uniform extracellular fluorescence a Fluorescence results do not confirm BBB translocation; 1. b NP component in brain extracellular space supports claim of its passage through the BBB; 5 2.2 and 2.3(3.4 and 5.5)
Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Table 3 . The numbers after the sentences in column 3 refer to the level of demonstrated NP brain entry. AAS: Atomic absorption spectroscopy; BBB: Blood-brain barrier; BBTB: Blood-brain tumor barrier; BMEC: Lamotrigine brain uptake Lamotrigine was determined by HPLC in homogenized brain after iv. injection of 125-nm lamotrigine-loaded poly-ε-(D,L-lactide-co-caprolactone) NPs HPLC results of NP component show bulk brain uptake; 1 [134] '[DNA-coated gold NPs] can be successfully delivered to specific brain locations across the BBB in mice using focused ultrasound'
Mice were iv. injected with 6-14-nm fluorescent-labeled DNA-coated gold NPs after unilateral microbubble injection and before ultrasound to open the BBB. The effected hemisphere showed more NPs (bright-field and fluorescence microscopy) than the contralateral hemisphere Resolution was not sufficient to verify delivery across the BBB; 1 [135] 'This strategy increased NP translocation into brain parenchyma'
CLSM of brain, stained for GFAP to localize astrocyte foot processes, from mice iv. injected with 180-nm ApoE4-coated, fluorescent dye-labeled, lipid, polysorbate-80 NPs showed some fluorescence from the NPs not surrounded by fluorescence from GFAP Fluorescence from the NP label appears to be in brain parenchyma; 5 [25] 'Gamma scintigraphicimages showed . . . the radiolabeled formulations successfully crossed BBB' a Whole rat gamma scintigraphy was conducted after iv. injection of 24-nm AZT-containing 99m Tc-labeled nanoliposomes. b AZT was determined by HPLC in homogenized brain of in situ blood-perfused rats after iv. Epi-fluorescence microscopy of rat brain 24 h after iv. injection of 278-nm FITC and Brij 78-containing solid lipid NPs showed spherical fluorescence not associated with an endothelial marker Spherical fluorescence in absence of blood vessel marker fluorescence suggests NP brain parenchymal entry; 5 [139] Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Table 3 . The numbers after the sentences in column 3 refer to the level of demonstrated NP brain entry. AAS: Atomic absorption spectroscopy; BBB: Blood-brain barrier; BBTB: Blood-brain tumor barrier; BMEC: '[NP] rapidly and effectively delivered drugs to the brain via the nose-to-brain pathway'
Mouse brain was IVIS imaged ex vivo and MRI imaged after intranasal dosing of 110-or 143-nm fluorescent and gadolinium-labeled cholera toxin or BSA NP Whole brain results using these methods show fluorescence and gadolinium in the brain; 1 11.6 [142] NP delivery to the brain Ex vivo brain was IVIS imaged after iv. injection of fluorescent-labeled, microbubble complexed, albumin NPs and ultrasound to brain tumor bearing mice Whole brain results using this method show fluorescence in the brain; 1 [143] Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Confocal microscopy of mouse brain after iv. injection of 126-nm doxorubicin, mitomycin C and internalizing peptide-labeled terpolymer-lipid hybrid NP after iv. injection of Texas-red-dextran to visualize blood vessels showed particulate doxorubicin fluorescence not associated with blood vessels
Punctate fluorescence attributed to doxorubicin not associated with blood vessels suggests brain parenchymal NP entry; 6 [145] Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Table 3 . The numbers after the sentences in column 3 refer to the level of demonstrated NP brain entry. AAS: Atomic absorption spectroscopy; BBB: Blood-brain barrier; BBTB: Blood-brain tumor barrier; BMEC: dependent, increasing from less than 96 h after 60 μg to approximately 480 h after 1600 μg [81] , suggesting the quantity of NPs in brain parenchyma influence their duration of persistence in that compartment. Some studies reported the brain level of the NP or its components at multiple times after its peripheral administration. Some studies also reported blood and/or peripheral organ levels. The reported values are shown in Supplementary Figure 1 . To be able to visually compare the rates of NP/component increase or decrease over time given the wide range of levels and timecourses among the studies, the results were normalized to the dose for CED studies or first reported value for other studies and shown as double log figures. It is expected that NPs that entered brain parenchyma would persist longer in the brain than NPs that did not cross the BBB, and longer than in the blood. Most reports of brain NP or component determination over time did not have many values (range for the non-CED and non-microdialysis studies: 2-16, median: 5) discouraging rigorous pharmacokinetic analysis or estimate of NP residence to infinity. Noncompartmental mean residence time (MRT) to the last sample was determined using Phoenix 8.1 WinNonLin. The MRT of NPs or their components after peripheral or intranasal administration is generally less than after CED, suggesting less than 100% of the NPs or components entered brain parenchyma. Good agreement was obtained between the MRT results and author reported half-lives for the same datasets (Tables 1 & 4) . The MRT was similarly calculated for NP, or its component, in blood from the studies that determined them at multiple times after NP administration. The results are shown in parentheses in Table 4 . The timecourse and MRTs for the NP or its component in the brain, blood and peripheral organs were often similar ( Supplementary Figure 1 & Table 4 ). This could be due to most or all of the NP/component in the brain residing in blood within the brain or adhering to the luminal wall of BMECs and being cleared from brain at the same rate as blood clearance from peripheral circulation. Exceptions were seen in two reports where the brain MRT was considerably longer than blood MRT [17, 58] , suggesting NP distribution beyond the vascular compartment. However, evidence of brain parenchymal entry was not provided.
Studies classified according to the criteria in Table 3 as demonstrating brain parenchymal entry (levels 5 and 6) that reported brain NP or component levels at multiple times are shown in Supplementary Figure 1D and E. Brain levels often increased over time or decreased more slowly than in studies classified as not showing brain parenchymal entry. Brain levels often decreased more slowly than blood levels in studies shown in Supplementary Figure 1D and E than B or C. There is some concordance between the classification levels and NP/component timecourse in the brain, suggesting the rate of NP/component clearance from the brain reflects the absence or presence of brain parenchymal entry.
The evidence of NP parenchymal entry may not be from the same measure as that providing the brain timecourse (e.g., TEM showing NP in brain cells, whereas NP/marker residence determined by HPLC). When NP or component was determined by radioactivity, neutron activation analysis, IVIS imaging, fluorescence, HPLC, atomic absorption spectroscopy, inductively coupled plasma-optical emission spectroscopy, inductively coupled plasma-mass spectrometry or LC-MS, it could be that only a fraction was in brain parenchyma. A risk of concluding NP brain entry or brain parenchymal entry from a component of the NP, such as an incorporated fluorescent dye or a metal component of a metal-or metal oxide-containing NP, is that the dye or metal might be released and its distribution does not represent the NP. For example, it was concluded that dye clearance from the brain in 24 h was 'most likely due to degradation of the dye itself rather than actual clearance of the NPs from the brain' [82] . Similarly, metal analysis by neutron activation analysis, atomic absorption spectroscopy, inductively coupled plasma-optical emission spectroscopy or inductively coupled plasma-mass spectrometry may be informing about released ion, particularly from readily soluble NPs such as those containing copper, silver and zinc.
In contrast, the results of many studies which did not demonstrate NP distribution in brain parenchyma showed more rapid clearance of brain-associated NPs ( Table 4 & Supplementary Figure 1 ). Many studies did not remove blood from the brain. The decline of NPs within a few hours in the brain, at a rate similar to its decline in blood, and more rapidly than the decline from peripheral organs, may be due to lack of brain parenchymal entry. Such results suggest that only some, or none, of the NPs crossed the BBB. The NPs may have adhered to the luminal wall of brain vasculature or localized in cellular or membrane components of the BBB, and subsequently distributed away from these sites into blood circulating through the brain. In studies that did not use sufficient methods to demonstrate NP brain parenchymal entry, the NPs may indeed have crossed the BBB. However, the methods do not verify that. If procedures are used to rule out the contribution of NPs in blood and adherence to BMECs, NP persistence in the brain may indicate successful distribution across the BBB.
Conclusion
The BBB and BCSFB provide a significant challenge to deliver substances into the brain to access neural, glial and cancer cells. Verification that the substance has entered into the compartment that houses these cells (brain parenchyma) is not trivial. Experimental results are sometimes overinterpreted to suggest successful delivery of substances that might directly act on cells in the brain when verification of brain parenchymal entry is lacking. An understanding of the anatomy and location of the barriers (BBB and BCSFB) to brain parenchymal entry helps one interpret if a substance has entered brain parenchyma. Visual and procedural methods have been used to verify brain parenchymal entry. In this article, methods have been classified as to the level of verification of brain parenchymal entry and then critically applied to studies. The BBB can be bypassed by direct substance introduction into the brain by CED that often results in prolonged residence of the substance in the brain. It is suggested that prolonged substance residence in the brain after its peripheral (e.g., iv.) administration suggests brain parenchymal entry. It is hoped that this guide will help researchers and reviewers be more precise in their demonstration and interpretation of substance distribution in the brain.
Future perspective
As the study of NP biological interaction matures, there is greater understanding of how to critically assess NP effects and their distribution. If the criteria and methods that demonstrate bulk brain and brain parenchymal entry proposed herein are employed by researchers and reviewers, there will be more precise reporting of brain NP distribution. More realistic result interpretation will enable more realistic clinical benefit expectation. This will enhance the credibility of this endeavor and help investigators engage in best practice research.
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Executive summary
• The anatomy and function of the blood-brain (BBB) and blood-cerebrospinal fluid barriers are reviewed.
• Exposure routes to bypass the BBB (convection-enhanced delivery and uptake from the nasal cavity by cranial nerves) are described. • Visual and procedural methods to determine nanoparticle (NP) brain and brain parenchymal entry are presented.
• Criteria are proposed to classify levels of experimental result evidence that demonstrate NP bulk brain or brain parenchymal entry. • Studies of NP brain entry or distribution across the BBB are summarized, critiqued and evaluated using the classification levels to interpret if the study shows NP bulk brain or brain parenchymal entry. • NP or component persistence in the brain after systemic or intranasal administration compared with blood and peripheral organs and direct infusion by convection-enhanced delivery into the brain are compared with interpret support for NP distribution beyond the brain vasculature, into brain parenchyma.
